2013
Circulating MicroRNAs in Relation to EGFR Status and Survival of Lung Adenocarcinoma in Female Non-Smokers
Zhang H, Su Y, Xu F, Kong J, Yu H, Qian B. Circulating MicroRNAs in Relation to EGFR Status and Survival of Lung Adenocarcinoma in Female Non-Smokers. PLOS ONE 2013, 8: e81408. PMID: 24282590, PMCID: PMC3839880, DOI: 10.1371/journal.pone.0081408.Peer-Reviewed Original ResearchConceptsLung adenocarcinomaOverall survivalFemale patientsMiR-195MiR-122Survival outcomesPlasma levelsEGFR statusNon-smoking female patientsCox proportional hazards regressionKaplan-Meier survival analysisEGFR-mutant patientsProportional hazards regressionAdvanced disease stageEGFR mutation statusTime-dependent receiverMiR-122 expressionReal-time RT-PCRHazards regressionPoor prognosisPrognostic valueDisease stageNon smokersMutant patientsEGFR mutations
2012
PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer
Su D, Xu H, Feng J, Gao Y, Gu L, Ying L, Katsaros D, Yu H, Xu S, Qi M. PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer. Journal Of Translational Medicine 2012, 10: 31. PMID: 22369209, PMCID: PMC3305474, DOI: 10.1186/1479-5876-10-31.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overApoptosisApoptosis Regulatory ProteinsBlotting, WesternCalcium-Binding ProteinsCarcinoma, Ovarian EpithelialCell CycleCell Line, TumorCell ProliferationDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesGene SilencingGenetic VectorsHumansKaplan-Meier EstimateLentivirusMiddle AgedNeoplasm InvasivenessNeoplasm MetastasisNeoplasms, Glandular and EpithelialOvarian NeoplasmsRNA, MessengerRNA, Small InterferingStatistics, NonparametricTransfectionConceptsEpithelial ovarian cancerProgression-free survivalOvarian cancer progressionOvarian cancer cellsOvarian cancerFree survivalOverall survivalIndependent predictorsKaplan-Meier survival analysisEpithelial ovarian cancer tissuesMetastatic ovarian cancer cellsCancer progressionPDCD6 expressionResidual tumor sizeClinical pathological factorsEpithelial ovarian cancer correlatesCancer cellsOvarian cancer correlatesOvarian cancer tissuesHistologic typeClinical progressionTumor sizeDisease stageTumor gradeCancer correlates
2009
Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel
Su D, Smith SM, Preti M, Schwartz P, Rutherford TJ, Menato G, Danese S, Ma S, Yu H, Katsaros D. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 2009, 115: 2453-2463. PMID: 19322891, DOI: 10.1002/cncr.24282.Peer-Reviewed Original ResearchConceptsHigh stathmin expressionBetaIII-tubulinOvarian cancerTreatment responseOverall survivalStathmin expressionDisease progressionPaclitaxel treatmentResidual tumor sizePlatinum-based chemotherapyEpithelial ovarian cancerOvarian cancer patientsFresh tumor samplesMessenger RNA expressionBetaIII-tubulin expressionCytoreductive surgeryPatient agePolymerase chain reaction analysisPatient survivalTumor sizeDisease stagePlatinum chemotherapyPoor prognosisUnfavorable prognosisCancer patients
2008
TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival
Mu L, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Yu H. TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival. British Journal Of Cancer 2008, 99: 1357-1363. PMID: 18827819, PMCID: PMC2570529, DOI: 10.1038/sj.bjc.6604689.Peer-Reviewed Original ResearchConceptsHigher TGF-β1TGF-β1 genotypesTGF-β1T genotypeHazard ratioBreast cancerBreast tumorsProportional hazards regression analysisLower TGF-β1Early-stage diseaseHazards regression analysisBreast cancer patientsLate-stage diseaseShorter overall survivalFresh tumor samplesTGF-β1 concentrationsBreast cancer progressionClinical characteristicsIGFBP-3Overall survivalDisease recurrenceReceptor statusPatient survivalSurvival outcomesDisease stage
2006
Methylation of the insulin‐like growth factor binding protein‐3 gene and prognosis of epithelial ovarian cancer
WILEY A, KATSAROS D, FRACCHIOLI S, YU H. Methylation of the insulin‐like growth factor binding protein‐3 gene and prognosis of epithelial ovarian cancer. International Journal Of Gynecological Cancer 2006, 16: 210-218. PMID: 16445635, DOI: 10.1111/j.1525-1438.2006.00299.x.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBiopsy, NeedleCarcinomaCohort StudiesDNA MethylationFemaleHumansImmunohistochemistryInsulin-Like Growth Factor Binding Protein 3Multivariate AnalysisNeoplasm StagingOvarian NeoplasmsOvariectomyProbabilityPrognosisProportional Hazards ModelsRetrospective StudiesRisk FactorsSensitivity and SpecificitySurvival RateConceptsIGFBP-3 promoter methylationInsulin-like growth factorIGFBP-3Disease progressionOvarian cancerGrowth factorPromoter methylationEarly-stage ovarian cancerEpithelial ovarian cancer patientsResidual tumor sizeEarly-stage diseaseIGFBP-3 expressionEpithelial ovarian cancerOvarian cancer patientsUseful prognostic markerOvarian cancer progressionIGFBP-3 promoterMethylation-specific polymerase chain reactionIGFBP-3 genePathologic variablesTumor sizeDisease stageCancer patientsPolymerase chain reactionPrognostic markerMethylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer
Wiley A, Katsaros D, Fracchioli S, Yu H. Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. International Journal Of Gynecological Cancer 2006, 16: 210. DOI: 10.1136/ijgc-00009577-200601000-00034.Peer-Reviewed Original ResearchIGFBP-3 promoter methylationInsulin-like growth factorIGFBP-3Disease progressionOvarian cancerGrowth factorPromoter methylationEarly-stage ovarian cancerEpithelial ovarian cancer patientsResidual tumor sizeEarly-stage diseaseIGFBP-3 expressionEpithelial ovarian cancerOvarian cancer patientsUseful prognostic markerOvarian cancer progressionIGFBP-3 promoterMethylation-specific polymerase chain reactionIGFBP-3 genePathologic variablesTumor sizeDisease stageCancer patientsPolymerase chain reactionPrognostic marker
2004
Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer
Katsaros D, Cho W, Singal R, Fracchioli S, de la Longrais I, Arisio R, Massobrio M, Smith M, Zheng W, Glass J, Yu H. Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecologic Oncology 2004, 94: 685-692. PMID: 15350359, DOI: 10.1016/j.ygyno.2004.06.018.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerOvarian cancer prognosisOvarian cancerP16 methylationMethylation-specific PCRCancer prognosisPrimary epithelial ovarian cancerResidual tumor sizePromoter methylationRegression survival analysisOvarian cancer progressionFresh frozen tumor tissueP16 promoter methylationFrozen tumor tissueAdvanced diseaseNegative patientsOverall survivalPatient agePositive patientsPathological variablesTumor sizeDisease stageHistological gradeAggressive tumorsDisease progression
1996
Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue
Yu H, Diamandis E, Levesque M, Giai M, Roagna R, Ponzone R, Sismondi P, Monne M, Croce C. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Research And Treatment 1996, 40: 171-178. PMID: 8879683, DOI: 10.1007/bf01806212.Peer-Reviewed Original ResearchConceptsBenign breast diseaseProstate-specific antigenNormal breast tissueBreast diseaseBreast tumorsBreast tissueBreast cancerSpecific antigenBreast cancer tissuesSteroid hormone actionPSA positivityPSA levelsDisease stageProstatic adenocarcinomaPSA productionTumor markersStage IBBD tissueCancer tissuesFemale breastSteroid hormonesLow expressionPolymerase chain reaction amplificationTumorsChain reaction amplification
1995
Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer.
Yu H, Giai M, Diamandis E, Katsaros D, Sutherland D, Levesque M, Roagna R, Ponzone R, Sismondi P. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Research 1995, 55: 2104-10. PMID: 7538047.Peer-Reviewed Original ResearchConceptsProstate-specific antigenIR-PSABreast cancerCox proportional hazards regression modelEstrogen receptor-negative patientsEstrogen receptor-positive tumorsProportional hazards regression modelsIndependent favorable prognostic markerReceptor-negative patientsNode-positive patientsFavorable prognostic indicatorSurvival of patientsReceptor-positive tumorsRelapse-free survivalBreast cancer patientsFemale breast cancerHazards regression modelsEarly disease stagesFavorable prognostic markerProstatic epithelial cellsPSA statusBetter prognosisPositive tumorsPrognostic valueDisease stage
1994
Detection of prostate-specific antigen immunoreactivity in breast tumors
Diamandis E, Yu H, Sutherland D. Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Research And Treatment 1994, 32: 301-310. PMID: 7532468, DOI: 10.1007/bf00666007.Peer-Reviewed Original ResearchConceptsProstate-specific antigenPSA immunoreactivityProgesterone receptorP53 tumor suppressor gene productBreast tumorsProstate-specific antigen immunoreactivitySeminal prostate-specific antigenProgesterone receptor-positive tumorsSensitive immunofluorometric procedureReceptor-positive tumorsEarly disease stagesTumor suppressor gene productBreast tumor extractsSuppressor gene productWestern blot analysisDisease stageProstate carcinomaAntigen immunoreactivityTumor extractsTumor specimensClinical practiceImmunoreactivityTumorsYoung womenImmunofluorometric procedure